Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications

Patrizia Ciammella, Stefano Luminari, Luca Arcaini, Andrea Riccardo Filippi

Research output: Contribution to journalArticle

Abstract

Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoproliferative disorders. Treatment strategies for FL may include several therapeutic choices, ranging from a “watchful waiting” approach to stem cell transplantation, mostly depending on staging, age, risk factors, and disease burden at diagnosis. The high radiosensitivity of FL compared with other solid tumors has been known since the beginning of radiotherapy treatment in lymphoma patients. Doses of 24 to 40 Gy were considered appropriate in first line curative treatment for localized disease (stages I-II), but several publications investigating low-dose radiotherapy (LDRT) of 4Gy (2 × 2Gy) reported an overall response rate surprisingly high. Due to its high local efficacy and negligible toxicity, LDRT might be offered to both early and advanced stage FL patients in combination with new agents, at diagnosis or after several lines of systemic therapy. The aim of this review is to summarize and discuss the current knowledge on LDRT for FL and its potential application in a curative setting in combination with new drugs for both early and advanced disease.

Original languageEnglish
JournalHematological Oncology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Follicular Lymphoma
Radiotherapy
Watchful Waiting
Therapeutics
Lymphoproliferative Disorders
Age Factors
Radiation Tolerance
Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Publications
Lymphoma
Pharmaceutical Preparations
Neoplasms

Keywords

  • follicular lymphoma
  • low-dose radiotherapy
  • lymphoma
  • non-Hodgkin
  • radiotherapy
  • treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Renewed interest for low-dose radiation therapy in follicular lymphomas : From biology to clinical applications. / Ciammella, Patrizia; Luminari, Stefano; Arcaini, Luca; Filippi, Andrea Riccardo.

In: Hematological Oncology, 01.01.2018.

Research output: Contribution to journalArticle

@article{b3e0bbbd9f714518baefac49399b887d,
title = "Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications",
abstract = "Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoproliferative disorders. Treatment strategies for FL may include several therapeutic choices, ranging from a “watchful waiting” approach to stem cell transplantation, mostly depending on staging, age, risk factors, and disease burden at diagnosis. The high radiosensitivity of FL compared with other solid tumors has been known since the beginning of radiotherapy treatment in lymphoma patients. Doses of 24 to 40 Gy were considered appropriate in first line curative treatment for localized disease (stages I-II), but several publications investigating low-dose radiotherapy (LDRT) of 4Gy (2 × 2Gy) reported an overall response rate surprisingly high. Due to its high local efficacy and negligible toxicity, LDRT might be offered to both early and advanced stage FL patients in combination with new agents, at diagnosis or after several lines of systemic therapy. The aim of this review is to summarize and discuss the current knowledge on LDRT for FL and its potential application in a curative setting in combination with new drugs for both early and advanced disease.",
keywords = "follicular lymphoma, low-dose radiotherapy, lymphoma, non-Hodgkin, radiotherapy, treatment",
author = "Patrizia Ciammella and Stefano Luminari and Luca Arcaini and Filippi, {Andrea Riccardo}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/hon.2538",
language = "English",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",

}

TY - JOUR

T1 - Renewed interest for low-dose radiation therapy in follicular lymphomas

T2 - From biology to clinical applications

AU - Ciammella, Patrizia

AU - Luminari, Stefano

AU - Arcaini, Luca

AU - Filippi, Andrea Riccardo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoproliferative disorders. Treatment strategies for FL may include several therapeutic choices, ranging from a “watchful waiting” approach to stem cell transplantation, mostly depending on staging, age, risk factors, and disease burden at diagnosis. The high radiosensitivity of FL compared with other solid tumors has been known since the beginning of radiotherapy treatment in lymphoma patients. Doses of 24 to 40 Gy were considered appropriate in first line curative treatment for localized disease (stages I-II), but several publications investigating low-dose radiotherapy (LDRT) of 4Gy (2 × 2Gy) reported an overall response rate surprisingly high. Due to its high local efficacy and negligible toxicity, LDRT might be offered to both early and advanced stage FL patients in combination with new agents, at diagnosis or after several lines of systemic therapy. The aim of this review is to summarize and discuss the current knowledge on LDRT for FL and its potential application in a curative setting in combination with new drugs for both early and advanced disease.

AB - Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoproliferative disorders. Treatment strategies for FL may include several therapeutic choices, ranging from a “watchful waiting” approach to stem cell transplantation, mostly depending on staging, age, risk factors, and disease burden at diagnosis. The high radiosensitivity of FL compared with other solid tumors has been known since the beginning of radiotherapy treatment in lymphoma patients. Doses of 24 to 40 Gy were considered appropriate in first line curative treatment for localized disease (stages I-II), but several publications investigating low-dose radiotherapy (LDRT) of 4Gy (2 × 2Gy) reported an overall response rate surprisingly high. Due to its high local efficacy and negligible toxicity, LDRT might be offered to both early and advanced stage FL patients in combination with new agents, at diagnosis or after several lines of systemic therapy. The aim of this review is to summarize and discuss the current knowledge on LDRT for FL and its potential application in a curative setting in combination with new drugs for both early and advanced disease.

KW - follicular lymphoma

KW - low-dose radiotherapy

KW - lymphoma

KW - non-Hodgkin

KW - radiotherapy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85052366555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052366555&partnerID=8YFLogxK

U2 - 10.1002/hon.2538

DO - 10.1002/hon.2538

M3 - Article

AN - SCOPUS:85052366555

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

ER -